$SLS
AI分析生成日 May 13, 2026
AI Score
Sell$SLS
SELLAS Life Sciences Group
$SLSNASDAQHealthcareSmall-Cap
SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies, with lead asset galinpepimut-S (GPS) for hematologic cancers.
Market Cap
$0.08B
Revenue (TTM)
$0.01B
N/A
Net Income (TTM)
-$0.03B
N/A
EPS (TTM)
-$1.20
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$1-$5
Beta
1.95
Dimension Scores
Fundamental
15Technical
32Sentiment
38Risk / Reward
22Momentum
35Financial Health
Profitability
20weak
Growth
38weak
Liquidity
30strong
Solvency
17moderate
Efficiency
13moderate
Valuation, technical analysis, investment thesis, risk assessment and more for $SLS
Free · No credit card required
免責事項: AI生成の分析は教育目的のみです。投資アドバイスではありません。必ず資格のあるファイナンシャルアドバイザーにご相談ください。